Primary Antibodies

Primary antibodies are Y-shaped glycoproteins that bind to a specific antigen with high specificity and affinity. The antigen can be a small molecule, peptide, or protein. Due to their high affinity, and high specificity, they are used in protein localization, purification, and quantification. Primary antibodies can be monoclonal or polyclonal depending on the epitopes they bind to; monoclonal antibodies bind to one specific epitope on antigens, whereas polyclonal antibodies bind to multiple different epitopes on the antigen.

OriGene offers monoclonal and polyclonal primary antibodies from various species with broad applications. Our antibodies are validated for applications like: IHC, ICC, ELISA, FACS, and WB. Over the last decade, we have developed our own branded antibodies, including TrueMAB?, UltraMAB?, and TrueRAB?. Our antibodies have been well-cited for their high specificity and affinity.

View all primary antibodies

Featured products and services:

ABAT

ABAT

ACTA2

ACTA2

ADIPOQ

ADIPOQ

AFP

AFP

AGR2

AGR2

ALDH1L1

ALDH1L1

ALK

ALK

ALX4

ALX4

AMACR

AMACR

ANO1

ANO1

AR

AR

BBOX1

BBOX1

BCL2

BCL2

BID

BID

BMP4

BMP4

BTLA

BTLA

BUB1B

BUB1B

C14orf166

C14orf166

CA12

CA12

CD13

CD13

CD19

CD19

CD1C

CD1C

CD2

CD2

CD274

CD274

CD38

CD38

CD3E

CD3E

CD4

CD4

CD40

CD40

CD44

CD44

CD5

CD5

View all

Antibody specificity
Proper Antibody Design: keeps Specificity in Mind
Antibody validation
Locked on Target: Antibody Validation 101
Antibodies and Cervical Cancer
Antibodies and Cervical Cancer
Antibody in neuroscience research
Antibodies in Neuroscience Research
Biomarkers for liver diseases
Biomarkers for liver diseases
Antibody and leukemia
Antibodies and Leukemia
Biomarkers in Traumatic Brain Injury
Biomarkers for the diagnosis of TBI

Popular marker citations


Anti-LGR5 Antibody


LGR5

Title: LGR5 + epithelial tumor stem-like cells generate a 3D-organoid model for ameloblastoma.

PubMed ID: 32382005

Figure legend: "a Expression of?LGR5?in different histopathological types of AM ( n = 15). Scale bars, 20 ?m. NAT normal adjacent tissue (same patient). b The quantification of H-score of LGR5 expression in AM ( n = 15) and odontogenic cyst (OC) ( n = 6). H-Score of each sample was analyzed at least nine different areas by color deconvolution of ImageJ software and data are mean ? SD. Two-tailed unpaired Student?s t test. **** p < 0.0001. c Dual-color immunofluorescence study showed that about 66.3% of LGR5 signal was co-localized with the expression of pan-cytokeratin (Pan-CK) in the solid AM tissues ( n = 3). About 68.6% and 74.1% of LGR5 + cells co-expressed ALDH1 and OCT4, respectively. Scale bars, 20 ?m. The representative images are from the follicular AM. d The quantification of correlation coefficient of LGR5 and epithelial biomarker (Pan-CK) and stem cell-related genes (ALDH1 and OCT4) in the solid AMs ( n = 3). Each group was calculated at least three different areas by CellProfiler software and data are mean ? SD."

View Product | View Citation

Anti- CD163 Antibody


CD163

Title: Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.

PubMed ID: 34867934

Figure legend: "COL1A1 is expressed by cells of myeloid origin and AMs. COL1A1 expression in fresh BAL cultures from a Non-IPF patient with CTD-ILD, stained with rabbit anti-human-COL1A1 and ToPro-633 nuclear stain and (A) mouse isotype control, (B) mouse anti-CD45 and (C) mouse?anti-CD163?antibodies. Arrows indicate CD45 and?CD163?positive cells expressing COL1A1. "?CellProfiler software and data are mean ? SD. "

View Product | View Citation

Anti- PD-L1 Antibody


PD-L1

Title: Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.

PubMed ID: 29607153

Figure legend: "Immunohistochemical staining of PD-L1 in NSCLCs, showing 100%, 30%, 0% PD-L1-positive tumor cells stained, respectively (400? magnification, bar =50 ?m). (A,B,C) SP263 assay demonstrating PD-L1 positive tumor cells; (D,E,F)?UMAB228?assay demonstrating PD-L1 positive tumor cells; (G,H,I) SP142 assay demonstrating PD-L1-positive tumor cells. NSCLCs, non-small cell lung cancer; PD-L1, programmed cell death ligand-1."

View Product | View Citation

Anti- CD3E Antibody


CD3E

Title: Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury.

PubMed ID: 36472908

Figure legend: "Selection and annotation of areas of diffuse alveolar damage in COVID-19 lung tissues for transcriptomic analysis. ( A ) Merged immunofluorescence (IF) images of the lung samples from patients A, B and C (scale bars: 5mm, pan cytokeratin-green, DNA-blue, CD3-red, CD68-yellow). n=47 areas of interest (AOI) selected for transcript profiling are highlighted (blue circles-mild/moderate and magenta circles-severe pathology), of which n=46 passed quality control after sequencing. Labelled areas correspond to higher magnification examples in B . ( B ) Representative IF images of AOIs demonstrating the morphology and immune infiltrate observed within areas of severe and mild/moderate diffuse alveolar damage. AOIs spanned on average 0.2mm 2 (range: 0.05 to 0.33mm 2 ) with exclusion of empty space. ( C ) The proportion of CD3 + and CD68 + cells of total nucleated cells were derived from the immunofluorescent imaging, plotted for each AOI and coloured by histological severity (mild/moderate-blue, severe-magenta) or inclusion of bronchiolar epithelium (grey). AOI are annotated by patient: A ? circle, B ? triangle and C - square. ( D ) Differential gene expression between areas of severe and mild/moderate damage. Coloured and annotated genes have a fold change expression > 1.5 and a Benjamini-Hochberg (BH) adjusted p-value <0.05. ( E ) Selected GO biological processes significantly over-represented in genes differentially expressed between mild and severe areas of damage (BH corrected p < 0.05, one-sided Fisher?s exact test); see also Supplementary Table 3 for differentially expressed genes and all over-represented pathways. "

View Product | View Citation

Our Antibodies